Challenges and potential solutions to innovative vaccine development for developing countries

Procedia in Vaccinology

Volumn 1, Issue 1, 2009, Pages 183-188

  Milstien, Julie ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

innovation; vaccine access; vaccine development; vaccine pricing; willingness to pay

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MENINGITIS VACCINE; VACCINE;

ARTICLE; COMPETITION; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG RESEARCH; FUNDING; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; HUMAN; INVESTMENT; MARKET; MONEY; PATENT; PRIORITY JOURNAL; SCALE UP; TECHNOLOGY;

EID: 71549156871     PISSN: 1877282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.provac.2009.07.031     Document Type: Article

References (14)

1. http://www.vaccineamc.org/.
2. http://www.meningvax.org/faq.htm.
3. http://www.gavialliance.org/.
4. Jadhav S., Datla M., Kreeftenberg H., and Hendriks J. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 26 13 (2008) 1611-1615 Epub 2008 Feb 6
5. http://www.who.int/immunization_standards/vaccine_quality/pq_vaccines/en/index.html.
6. Milstien, Julie B., Gaulé, Patrick, Kaddar, and Miloud. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 25 44 (2007) 7610-7619
7. Batson, A. and Whitehead, P. Vaccine economics: assuring vaccines are developed for, and available in, developing countries. In press. New Generation Vaccines, 4th edition, eds MM Levine et al. New York: Marcel Dekker, Chapter 7.
8. http://www.unicef.org/supply/files/Product_Menu_23_Sept_2008.pdf.
9. http://www.guardian.co.uk/business/2009/feb/13/glaxo-smith-kline-cheap-medicine; IFPMA, Industry Commitment to Global Access. Statement May 5, 2008.
10. Sow S.O., Diallo S., Campbell J.D., Tapia M.D., Keita T., Keita M.M., Murray P., Kotloff K.L., and Levine M.M. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J. 24 6 (2005) 533-537
11. http://www.gavialliance.org/performance/country_results/index.php?contID=1&countID=42 - proposal October 2004 for pentavalent vaccine.
12. World Health Organization. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. Wkly epidemiol rec 81 47 (2006) 445-452
13. Data from Hib Initiative staff and website, http://www.hibaction.org/, accessed Nov 3, 2008.
14. Milstien J, Costa A, Jadhav S, Dhere R. Reaching International GMP Standards for Vaccine Production: Challenges for Developing Countries. Expert Review of Vaccines 2009, in press.